Product Categories
Featured products
Products/Services(55items)
news list
-
![Marrakech Patent Claim Drafting Tool [On-Demand Webinar]](https://image.mono.ipros.com/public/news/image/1/0f9/127202/IPROS13455807943524281802.png?w=280&h=280)
Marrakech Patent Claim Drafting Tool [On-Demand Webinar]
In the webinar, we will introduce how Markush Editor revolutionizes the creation of patent claims through a video lasting approximately 35 minutes. Markush claims are typically complex and labor-intensive, but by using Markush Editor, digital transformation (DX) becomes possible, reducing a task that previously took two weeks to just two days. Please join this webinar to see the effects for yourself. 【Overview】 - Introduction to Markush Editor - Presentation of specific operational images through a demo - Automatic creation of Markush structures from example structure groups - Inclusion check of example structures against Markush structures - Adjustment of Markush structures - Automatic generation of Markush claim drafts 【How to Watch】 Click on "MarkushEditor On-Demand Webinar" under "Related Links" below, download the PDF, and click the link button in the PDF to watch the webinar.
-

Excelra announces partnership with Patcoar.
Excelra has announced a partnership with Patcore to provide Japanese customers access to Excelra's scientific data and analytics products. Excelra is one of the world's leading companies in data and digital insights. Its GOSTAR platform is the largest manually curated medicinal chemistry information database, offering comprehensive and structured SAR (structure-activity relationship) data on over 9 million compounds. Excelra's GOBIOM includes the most extensive manually curated collection of verified and estimated biomarkers, providing critical insights into the relationship between biomarkers (biological indicator compounds) and diseases. Patcore is a highly specialized informatics company that supports researchers in the life sciences and chemical industries. This partnership leverages Patcore's strengths, which include experience working with some of Japan's largest pharmaceutical companies, biotechnology firms, chemical companies, and government agencies, to support Excelra's growth in Japan. For more details, please visit our website at the link below.
-
Chemical.AI and Chemaxon announce collaboration in the integration of scientific information software.
Chemical.AI, a global leader in artificial intelligence (AI) for synthetic route design and prediction, and Chemaxon, a leading company in chemical and biological software development, have announced a strategic partnership that will allow access to Chemical.AI's reverse synthesis tool, ChemAIRS, as an option from Chemaxon's drug discovery platform, Design Hub. This collaboration creates compatibility between Chemical.AI's ChemAIRS and Chemaxon's Design Hub, enabling a seamless user workflow and one-stop service that integrates compound design tracking and prioritization features from Design Hub with the innovative synthetic routes generated in minutes using ChemAIRS's diverse strategies. For more details, please visit our website.
-

Chemaxon announces the appointment of its new CEO, Richard Jonas.
Chemaxon, a leader in the development of cheminformatics software for life sciences research, has announced the appointment of Richard Jones as Chief Executive Officer (CEO). Richard succeeds the owner, Ferenc (Csizi) Csizmadia, in this role. Csizi will continue to serve as a founder while focusing on the establishment of Ancestralize, which is centered on health and well-being in the digital age. Additionally, coinciding with Mr. Richard's appointment, Chemaxon's Budapest office has relocated to the newly constructed environmentally friendly office park, Váci Greens, on the east side of the Danube River. A new logo and spelling have also been announced. For more details, please visit the news article on our company's homepage via the link below.
-

ChemAxon's response to the "Log4Shell" vulnerability.
▶ChemAxon's Response to CVE-2021-44228 ("Log4Shell") and CVE-2021-45046 Initial Release: December 15, 2021 Update: January 3, 2022 This vulnerability was disclosed by the Apache Log4j project on December 9, 2021 (Thursday). If exploited, it could allow remote attackers to execute code on the server if the system logs a string value controlled by the attacker to the affected endpoint. Immediately upon recognizing this vulnerability, ChemAxon evaluated all cloud hosting systems and on-premises software for customers, identified those that could be affected, and systematically began to address any exposures. All affected ChemAxon products have been updated to use log4j2.16, so no new incidents pose additional threats. For more details, please visit the Patcore or ChemAxon website.
Company Blog
-
なぜ今、エンジニアとR&Dチームにスマートなイノベーションツールが必要なのか?
エンジニアリング組織とR&D組織は、今まさに重要な転換点に立っています。Capgemini による新たなグローバル調査は、明確なトレンドを示しています。
-
Patsnap と Uncountable、R&Dチーム向けAI搭載 Formulation Agent の提供に向けて提携
IP、科学的知見、そしてラボデータを統合する初の取り組みにより、処方開発を変革 米国カリフォルニア州サンフランシスコおよび英国ロンドン —[2025年11月20日]— IPおよびR&Dインテリジ...
-
特許調査の真実:完璧という神話を覆す
あなたは特許出願を行いました。
-
Patsnap、SOC2 Type1 認証を取得
Patsnapでは、お客様のデータを保護することが、常に私たちの取り組みの中心にあります。
-
Med Tech & Med Device の知的財産戦略:主要な課題と成長機会
医療技術および医療機器分野は、AIを活用した診断や3Dプリントによるインプラントなどの技術的ブレークスルーにより、急速なイノベーションの段階にあります。医療機器分野は、2025年末までに市場規模...
Aboutパトコア
PatCore for drug discovery, chemical substance management, and chemical patent DX support!
Patocoa Inc. is a specialized company in drug discovery support systems. Additionally, we focus on improving and streamlining compliance-related operations concerning regulated substances, and we have provided various solutions to pharmaceutical companies, chemical companies, universities, and government agencies. We contribute to accelerating drug discovery and reducing costs with our cutting-edge chemoinformatics systems.





